Jennifer Herrera retweeted
Association of RPS20 Loss-of-Function Variants With Colorectal Cancer Risk in a Cohort of Over 950,000 Individuals.
Read the full article. brnw.ch/21wVoLB
#ColorectalCancer #crcsm
Check out our latest #research on #genediseasevalidity for hereditary cancer genes, published with @SpringerNature in @GenomeMedicine
rdcu.be/euoNj
8
Jennifer Herrera retweeted
Now an abstract from our friends at @AmbryGenetics presented by Jennifer Herrera-Mullar.
Patients with CTNNA1 pathogenic variants had no increased risk of lobular breast cancer as compared to controls and lower risk of gastric cancer as compared to CDH1.
Jennifer Herrera retweeted
Ambry will be at ASHG on November 1-5 in Washington, DC. Hear the latest advances in genetic and genomic research. Ambry has several informative posters and presentations you won’t want to miss! For more information, visit
hubs.ly/Q024wQwt0 #ASHG2023 #genomics
Jennifer Herrera retweeted
In the largest series of POT1 heterozygotes to date, we confirm POT1 as a melanoma predisposition gene and provide new data on associations with sarcoma and kidney cancer. hubs.ly/Q01_QNZP0 #YouKnowYourPatients #AmbryKnowsGenes
Jennifer Herrera retweeted
POT1 #cancerpredisposition gene: enrichment of melanoma and sarcoma in individuals heterozygous for POT1 pathogenic variants. #cancergenetics @JeniHMullar @carrieotype bit.ly/3OFlnVR
Jennifer Herrera retweeted
Ambry is looking forward to the Montreal BRCA Symposium! Check out our posters, which will be on display Tuesday, May 2. The rest of our posters and presentations are listed at hubs.ly/Q01Ngrxh0
#BRCA2023 #breastcancer #ovariancancer #genetictesting #AmbryKnowsGenes
You can help us reach Nicholas's Kids Heart Challenge $250 goal. Donate today!
bndfr.com/2Yk4q
24
You can help us reach Nicholas's Kids Heart Challenge $250 goal. Donate today!
bndfr.com/2Yk4q
16
Jennifer Herrera retweeted
Jennifer Herrera-Mullar, Principal Clinical Scientist from Ambry Genetics, discusses Ambry's poster, "Biallelic Variants in NTHL1 and MSH3 in Individuals Ascertained from a Multigene Panel Testing (MGPT) Cohort: a Descriptive Analysis," presented at CGA-IGC in Nashville, TN.














